RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:2 weeks: It’s all it took for Merck to get AA
Ben, you are a pumper as none of your posts are objective. You also have pretty thin skin as it seems you still think daily about someone who posted on this board years ago. Everything I mentioned are very clear statements made by the company and its only analyst. Usually, people change their position regarding revenues being pushed back 2 years based on something. If Uddin thought AA and revenues were coming in Jan 2023, like you have always projected, I don't think he would have reduced his price target and push back his timelines. I don't know all of the answers, neither do you believe it or not. Rather than change the topic regarding an old poster and/or keytruda which I have no interest in and wouldn't want any family member to have to go through the treatement, is it too much to ask for you to give me a logical reason the companies only analyst would push back his timeline and reduce his target price within 30-60 days of potnential AA and companies revenues. Try to stick to the facts, no more bs about keytruda and a buyout that isn't relavent